​​​The drugs were initially developed for diabetes but have also become hugely popular weight-loss drugs, under different brand names. The WHO stopped short of adding them to treat obesity alone,…

The deal includes an upfront purchase of 90 per cent equity stake for ₹188.5 crore, with the remaining 10 per cent to be acquired in 2030, for an additional consideration…

The study, published in PLOS One under the title “Smartphone use on the toilet and the risk of haemorrhoids,” offered eye-opening statistics.